Please login to the form below

Not currently logged in
Email:
Password:

Cephalon gets green light for cancer pain drug in EU

The European Commission has granted marketing authorisation for Cephalon's cancer pain drug Effentora
The European Commission has granted marketing authorisation for Cephalon's cancer pain drug Effentora.

Effentora, a buccal tablet formulation of fentanyl, which is indicated for the treatment of breakthrough cancer pain (BTCP) can now be marketed in the 27 EU member states as well as Norway and Iceland.

Cephalon, a US-based biopharmaceutical company, is seeking to bolster its standing in the European healthcare market.

Alain Aragues, president of Cephalon Europe, said: "Cephalon continues to build its presence in Europe, the Middle East and Africa, and activities are ongoing to make Effentora available quickly in the EU member countries."

"We are committed to bring new medications to the European markets that address the needs of patients with cancer," he added.

15th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics